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treatment therapy became more complex according to the 
guidelines.
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OBJECTIVE: Atypical antipsychotic agents are considered the
ﬁrst-line treatment of schizophrenia. Aim of present study was
to identify factors affecting the cost of schizophrenia treatment
with atypical antipsychotic agents. METHODS: A retrospective
database study was conducted in three public hospitals in Hong
Kong. Patients initiated on atypical antipsychotic agents (amisul-
pride, olanzapine, quetiapine and risperidone) between March
2003 and September 2003 for treatment of schizophrenia for at
least three months was recruited. Patient medical records were
reviewed for up to 12 months before and after initiation date of
the antipsychotic agents to retrieve baseline demographic and
clinical factors and health care resource utilization for schizo-
phrenia. A multiple regression model was used to identify demo-
graphic, clinical factors and choice of atypical antipsychotic
agents with signiﬁcant association to health care resource uti-
lization. RESULTS: Eighty-two patients were included in the
analysis. Thirty-four (41%) patients were male and mean age
was 43 ± 14 years. The mean cost per patient per month was
USD 431 ± 914 (1USD = 7.8HKD). Three factors were associ-
ated with direct medical cost of health care resource utilized: 1).
History of drug abuse (RR = 1.26; 95% CI = 1.05–1.52); 2).
prior use of depot antipsychotic (RR = 1.22; 95% CI =
1.05–1.42); and 3). previous duration of hospitalization before
initiation of atypical antipsychotic therapy (RR = 1.00; 95% CI
= 1.00–1.01). CONCLUSION: History of drug abuse, prior use
of depot antipsychotic, previous duration of hospitalization
appeared to be inﬂuential to direct medical cost of atypical
antipsychotic treatment. The choice of antipsychotic agents did
not appear to affect the cost of treatment.
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OBJECTIVE: To determine the cost-effectiveness (measured
using an incremental cost-utility ratio) of treating schizophrenia
patients with olanzapine versus risperidone, quetiapine, amisul-
pride, or oral typical antipsychotics. METHODS: European
SOHO is a 3-year, prospective, outpatient, observational study
associated with antipsychotic treatment in 10 European coun-
tries. Health care resource use and quality of life data (EuroQol
EQ-5D and UK population utility values) were collected at base-
line, 3, 6, and 12 months. UK health care costs were applied to
the resource use data for the 10 countries. Pair-wise incremental
costs and utilities were estimated between olanzapine-treated
patients and patients treated with each of the other oral antipsy-
chotics. Utility increments were used to estimate quality-adjusted
life-years (QALYs) gained. Incremental cost-utility ratios were
expressed as the additional cost per QALY gained. Bootstrap
replications provided an estimate of uncertainty. RESULTS: A
total of 10,972 patients were enrolled at baseline, 80% were eli-
gible for analyses at 12 months. Treatment with olanzapine is
more effective and less costly than quetiapine and amisulpride.
Treatment with olanzapine is more effective compared to treat-
ment with risperidone. The incremental cost is marginal. The
incremental cost-utility ratio was £5156 per additional QALY
gained. The bootstrap replications for the above comparisons
showed 100% of the replications falling below a £30,000 per
QALY threshold. Treatment with olanzapine is more effective
compared to treatment with oral typical antipsychotics. The
additional cost is marginal. The incremental cost-utility ratio 
for olanzapine versus oral typical treatment was £15,696 per
additional QALY gained. The bootstrap replications showed
97% of the replications below a $30,000 per QALY threshold.
CONCLUSIONS: Among SOHO patients, if a funding thresh-
old of £30,000 per QALY gained is assumed, olanzapine has a
high probability of being the most cost-effective treatment 
compared with atypical and oral typical antipsychotic 
medications.
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OBJECTIVES: To determine current neuroleptic drug utilization
patterns of ambulatory care schizophrenic patients in Germany.
METHODS: Analysis of routine prescription data for the years
2003/2004 of patients insured with the Techniker Krankenkasse
sickness fund (covering approximately 6-million insured persons
distributed across all German states) with a hospital diagnosis of
schizophrenia F20 (ICD-10) in 2003. RESULTS: In 2004, 3397
patients with schizophrenia received 28,434 prescriptions for
neuroleptic drugs. In total, 33.1% of prescriptions were for
typical, 66.9% for atypical neuroleptics. In total, 51.2% of
typical neuroleptics prescribed were high-potency, 48.8% low-
potency drugs. Olanzapine was the most frequently prescribed
atypical (26.5%), followed by Clozapine (21.1%), Risperidone
(19.2%), Quetiapine (14.5%), Amisulpride (11.9%), Ziprasi-
done (6.2%), and Zotepine (0.6%). Analysing prescriptions on
an individual patient level gave a similar picture. During a 12
month-period after their ﬁrst hospital stay in 2003, 1490 patients
(43.9%) were treated only with atypical neuroleptics, 555
patients (17.2%) were treated with an atypical plus a low-
potency typical neuroleptic as adjuvant therapy. In total, 280
patients (8.7%) received typical neuroleptics only and 245
patients (7.6%) were prescribed both high-potency typical and
atypical neuroleptics. The remaining patients received no ambu-
latory prescriptions for neuroleptics. Some of them may have
received drugs from hospital pharmacies which are not recorded
in the ambulatory prescription database. CONCLUSIONS:
Reaching 61% in 2003/2004, the proportion of schizophrenic
patients receiving atypical neuroleptic drugs as their main med-
ication in our study population is much higher than previously
thought and in the range of other western European countries.
However, the share of Clozapine is also much higher than in
most countries. Although this non-random sample is not repre-
sentative of the German population, major differences in pre-
scribing behaviour depending on a patient’s sickness fund are
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unlikely. Some bias due to above average socio-economic status
of the insured population cannot be excluded.
PMH33
FACTORS INFLUENCING ZIPRASIDONE PRESCRIBED DOSES
AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA
Mullins CD, Kuznik A
University of Maryland, Baltimore, MD, USA
OBJECTIVE: To describe factors which are associated with vari-
ations in the prescribed average daily dose of ziprasidone for the
treatment of schizophrenia. METHODS: We identiﬁed continu-
ously enrolled patients with a diagnosis of schizophrenia (ICD-
9 code 295.xx) between January 2001 and June 2003 from
Maryland Medicaid. The average daily dose prescribed was
deﬁned as the total amount dispensed divided by the days of
therapy. The effect of socio-demographic factors, recent hospi-
talization, psychiatric co-morbidities, and concurrent psychiatric
medication on the average daily dose prescribed was estimated
using ordinary least squares (OLS) regression. RESULTS: In the
sample of 1197 patients who met the inclusion criteria, the mean
average dose prescribed was 92mg per day (S.D.: 50mg). Males
were prescribed an 8mg higher average daily dose as compared
to females (p = 0.007). African Americans were prescribed 9mg
less as compared to Caucasians (p = 0.005). The average daily
dose prescribed increased if the patient was concurrently treated
with antidepressants by 8mg (p = 0.018), with antipsychotics by
16mg (p < 0.001), and with anticonvulsants by 12mg (p =
0.001). Patients who had a psychiatric hospitalization during the
30 days prior to initiation of therapy were prescribed average
daily doses that were 8mg higher, but this increase was not sta-
tistically signiﬁcant (p = 0.055). Patient age, the number of psy-
chiatric co-morbidities, and concurrent treatment with antimanic
and antianxiety medication were not found to statistically affect
prescribing patterns. CONCLUSION: Schizophrenia patients’
gender, race, and concurrent treatment medication signiﬁcantly
affect the decision makers prescribing patterns of ziprasidone in
terms of the average daily dose.
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OBJECTIVES: To evaluate 6-month clinical and economic out-
comes following initiation of long-acting injectable risperidone
(LAIR) in patients with schizophrenia/schizoaffective disorder.
METHODS: Data are collected via a secured web-based system,
retrospectively for 12-months and prospectively for 2-years.
Patient demographics, treatment and hospitalisation history,
reason for initiating new treatment, Clinical Global Impres-
sion—Severity (CGI-S), Global Assessment of Functioning (GAF)
and adverse event data are collected. This interim analysis
includes the ﬁrst 991 patients in Germany with at least 6 months
follow-up or who discontinued treatment during this 6 month
period. RESULTS: Of the 991 patients, 56% were male. Mean
age was 43 (±14) years, mean duration of illness at initiation of
LAIR was 10 (±10) years. A total of 79% were diagnosed with
schizophrenia whilst 17% had schizoaffective disorder. After 6-
months, 75% of patients still received their original starting
dose. Compared with the preceding 6-month period, fewer
patients required full hospitalisations (34% vs. 20%; p < 0.001).
Decreases from baseline were seen in the concomitant use of anti-
cholinergics (13.3% to 6.1%), antidepressants (18.1% to
11.8%), mood stabilisers (9.8% to 7.1%), benzodiazepines
(17.3% to 8.4%), and somatic medication (14.7% to 8.5%; all
comparisons p < 0.001). Compared to baseline, CGI-S ratings
improved from 4.7 to 3.8, and patient functioning (GAF)
increased from 46.7 to 58.0 at 6-months (both p < 0.001); 13%
of patients discontinued treatment with LAIR. Most frequent
reason (3.5%) was patient/family choice; 1.2% discontinued due
to adverse event. CONCLUSIONS: The 6-month interim data
show that the majority of patients initiated on LAIR remained
on stable doses. Discontinuation rates were low. Need for inpa-
tient care was reduced, as was use of psychotropic and somatic
concomitant medication. There was signiﬁcant and clinically rel-
evant improvement in illness and functioning. Longer term data
with larger sample size are being accrued to further explore these
outcomes over time.
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OBJECTIVES: From a longitudinal study, we observed the socio-
economic proﬁle and the occupational situation of a cohort of
schizophrenic patients over 1 year and we made an estimate of
the indirect costs in this population. METHODS: Occupations,
sources of income, health care and social situation were reported
regularly over a 1-year period by a group of 538 schizophrenic
outpatients. We speciﬁcally studied the population already inte-
grated into the workplace. Number and duration of work
absences were basic data for the calculation of indirect costs. In
this subgroup, we adopted the perspective of the Sickness Fund
(SF). The costing was performed by combining number and
duration of work absences, patient income levels in 2002, annual
number of workdays, SF rules for the coverage of workdays lost.
RESULTS: In our sample of 538 schizophrenic patients, 2% were
managers, 15% were white-collars, 5% were blue-collars, 8%
were unemployed and the rest of the population (70%) lived
without occupations or in occupation-aided structure. Work
absences occurred in 54% of managers with a median duration
of 184 days; this rate is at 36% for white-collars with a median
duration of 83 days; this rate is at 19% for blue-collars with a
median duration of 30 days. The median costs over 1-year due
to absenteeism at work were €7419, €3071, and €1100 for man-
agers, white-collars and blue-collars respectively. CONCLU-
SIONS: More than a quarter of our sample was employed and
integrated into society. We found that managers seemed to gen-
erate highest work absences in terms of number, duration and
costs; the position of managers and the level of related-stress
might have an impact on the natural course of the disease.
According to our ﬁndings, it is reasonable to estimate the indi-
rect costs of schizophrenia more accurately in the future.
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